These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 23403953)
1. Susceptibility of hepatoma-derived cells to histone deacetylase inhibitors is associated with ID2 expression. Tsunedomi R; Iizuka N; Harada S; Oka M Int J Oncol; 2013 Apr; 42(4):1159-66. PubMed ID: 23403953 [TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Munshi A; Kurland JF; Nishikawa T; Tanaka T; Hobbs ML; Tucker SL; Ismail S; Stevens C; Meyn RE Clin Cancer Res; 2005 Jul; 11(13):4912-22. PubMed ID: 16000590 [TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270 [TBL] [Abstract][Full Text] [Related]
4. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Pathil A; Armeanu S; Venturelli S; Mascagni P; Weiss TS; Gregor M; Lauer UM; Bitzer M Hepatology; 2006 Mar; 43(3):425-34. PubMed ID: 16583461 [TBL] [Abstract][Full Text] [Related]
5. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma. Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975 [TBL] [Abstract][Full Text] [Related]
6. Sodium butyrate-induced DAPK-mediated apoptosis in human gastric cancer cells. Shin H; Lee YS; Lee YC Oncol Rep; 2012 Apr; 27(4):1111-5. PubMed ID: 22160140 [TBL] [Abstract][Full Text] [Related]
8. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068 [TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells. Dos Santos Ferreira AC; Fernandes RA; Kwee JK; Klumb CE J Cancer Res Clin Oncol; 2012 Feb; 138(2):317-25. PubMed ID: 22131152 [TBL] [Abstract][Full Text] [Related]
10. BMP4 enhances hepatocellular carcinoma proliferation by promoting cell cycle progression via ID2/CDKN1B signaling. Ma J; Zeng S; Zhang Y; Deng G; Qu Y; Guo C; Yin L; Han Y; Shen H Mol Carcinog; 2017 Oct; 56(10):2279-2289. PubMed ID: 28543546 [TBL] [Abstract][Full Text] [Related]
11. The expression of tumor suppressor gene Cyld is upregulated by histone deacetylace inhibitors in human hepatocellular carcinoma cell lines. Kotantaki P; Mosialos G Cell Biochem Funct; 2016 Oct; 34(7):465-468. PubMed ID: 27570065 [TBL] [Abstract][Full Text] [Related]
12. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling. Shin H; Kim JH; Lee YS; Lee YC Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241 [TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells. Suenaga M; Soda H; Oka M; Yamaguchi A; Nakatomi K; Shiozawa K; Kawabata S; Kasai T; Yamada Y; Kamihira S; Tei C; Kohno S Int J Cancer; 2002 Feb; 97(5):621-5. PubMed ID: 11807787 [TBL] [Abstract][Full Text] [Related]
14. Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma. Zhang CZ; Chen GG; Merchant JL; Lai PB Cell Cycle; 2012 Jan; 11(2):322-34. PubMed ID: 22214764 [TBL] [Abstract][Full Text] [Related]
15. Effect of histone acetylation modification with sodium butyrate, a histone deacetylase inhibitor, on cell cycle, apoptosis, ploidy and gene expression in porcine fetal fibroblasts. Mohana Kumar B; Song HJ; Cho SK; Balasubramanian S; Choe SY; Rho GJ J Reprod Dev; 2007 Aug; 53(4):903-13. PubMed ID: 17558190 [TBL] [Abstract][Full Text] [Related]
16. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Rahman MM; Kukita A; Kukita T; Shobuike T; Nakamura T; Kohashi O Blood; 2003 May; 101(9):3451-9. PubMed ID: 12511413 [TBL] [Abstract][Full Text] [Related]
17. Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mühlethaler-Mottet A; Meier R; Flahaut M; Bourloud KB; Nardou K; Joseph JM; Gross N Mol Cancer; 2008 Jun; 7():55. PubMed ID: 18549473 [TBL] [Abstract][Full Text] [Related]
18. LncRNA ID2-AS1 suppresses tumor metastasis by activating the HDAC8/ID2 pathway in hepatocellular carcinoma. Zhou Y; Huan L; Wu Y; Bao C; Chen B; Wang L; Huang S; Liang L; He X Cancer Lett; 2020 Jan; 469():399-409. PubMed ID: 31730902 [TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Amin HM; Saeed S; Alkan S Br J Haematol; 2001 Nov; 115(2):287-97. PubMed ID: 11703323 [TBL] [Abstract][Full Text] [Related]
20. Decreased ID2 promotes metastatic potentials of hepatocellular carcinoma by altering secretion of vascular endothelial growth factor. Tsunedomi R; Iizuka N; Tamesa T; Sakamoto K; Hamaguchi T; Somura H; Yamada M; Oka M Clin Cancer Res; 2008 Feb; 14(4):1025-31. PubMed ID: 18281534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]